Management decisions in chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Interferon-alfa and cytarabine were previously standard initial treatments for chronic myeloid leukemia (CML).
• Allogeneic stem cell transplantation was an option for eligible CML patients.
• Imatinib has emerged as a novel single-agent therapy for CML.

Purpose of the Study:

• To evaluate the efficacy of imatinib in newly diagnosed chronic myeloid leukemia (CML) patients.
• To propose criteria for defining response, non-response, and response failure to imatinib therapy.
• To discuss alternative therapeutic strategies for patients failing imatinib and the role of stem cell transplantation.

Main Methods:

• Clinical assessment of hematologic and cytogenetic responses in CML patients treated with imatinib.
• Development of tentative criteria for evaluating imatinib treatment outcomes.
• Review of treatment strategies including imatinib, alternative therapies, and allogeneic stem cell transplantation.

Main Results:

• Imatinib demonstrated rapid and durable control of hematologic features in CML patients.
• A high rate of cytogenetic response was observed with imatinib monotherapy.
• Patient response to imatinib was noted to be variable.

Conclusions:

• Imatinib shows potential for substantial life prolongation in CML patients.
• Establishing clear criteria for response and failure is crucial for timely therapeutic adjustments.
• Patients not responding to imatinib may benefit from early initiation of alternative treatments or consideration of stem cell transplantation.